Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 175

1.

An intra-tumoral niche maintains and differentiates stem-like CD8 T cells.

Jansen CS, Prokhnevska N, Master VA, Sanda MG, Carlisle JW, Bilen MA, Cardenas M, Wilkinson S, Lake R, Sowalsky AG, Valanparambil RM, Hudson WH, McGuire D, Melnick K, Khan AI, Kim K, Chang YM, Kim A, Filson CP, Alemozaffar M, Osunkoya AO, Mullane P, Ellis C, Akondy R, Im SJ, Kamphorst AO, Reyes A, Liu Y, Kissick H.

Nature. 2019 Dec;576(7787):465-470. doi: 10.1038/s41586-019-1836-5. Epub 2019 Dec 11.

PMID:
31827286
2.

A Four-Group Urine Risk Classifier for Predicting Outcome in Prostate Cancer Patients.

Connell SP, Hanna M, McCarthy F, Hurst R, Webb M, Curley H, Walker H, Mills R, Ball RY, Sanda MG, Pellegrini KL, Patil D, Perry AS, Schalken J, Pandha H, Whitaker H, Dennis N, Stuttle C, Mills IG, Guldvik I; Movember GAP1 Urine Biomarker Consortium, Parker C, Brewer DS, Cooper CS, Clark J.

BJU Int. 2019 May 20. doi: 10.1111/bju.14811. [Epub ahead of print]

3.

Circulating microRNAs in plasma among men with low-grade and high-grade prostate cancer at prostate biopsy.

McDonald AC, Vira M, Walter V, Shen J, Raman JD, Sanda MG, Patil D, Taioli E.

Prostate. 2019 Jun;79(9):961-968. doi: 10.1002/pros.23803. Epub 2019 Apr 8.

PMID:
30958910
4.

Rise in Node-Positive Prostate Cancer Incidence in Context of Evolving Use and Extent of Pelvic Lymphadenectomy.

Taylor MA, Alemozaffar M, Master VA, Sanda MG, Filson CP.

Clin Genitourin Cancer. 2019 Jun;17(3):e494-e504. doi: 10.1016/j.clgc.2019.01.012. Epub 2019 Jan 26.

PMID:
30819637
5.

epiCaPture: A Urine DNA Methylation Test for Early Detection of Aggressive Prostate Cancer.

O'Reilly E, Tuzova AV, Walsh AL, Russell NM, O'Brien O, Kelly S, Dhomhnallain ON, DeBarra L, Dale CM, Brugman R, Clarke G, Schmidt O, O'Meachair S, Patil D, Pellegrini KL, Fleshner N, Garcia J, Zhao F, Finn S, Mills R, Hanna MY, Hurst R, McEvoy E, Gallagher WM, Manecksha RP, Cooper CS, Brewer DS, Bapat B, Sanda MG, Clark J, Perry AS.

JCO Precis Oncol. 2019;2019. doi: 10.1200/PO.18.00134. Epub 2019 Jan 14.

6.

Expanded Prostate Cancer Index Composite-26 (EPIC-26) Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life After Treatment for Localized Prostate Cancer.

Einstein DJ, Patil D, Chipman J, Regan MM, Davis K, Crociani CM, Wagner AA, Sanda MG, Chang P.

Urology. 2019 May;127:53-60. doi: 10.1016/j.urology.2019.02.004. Epub 2019 Feb 18.

PMID:
30790648
7.

Assigning value to preparation for prostate cancer decision making: a willingness to pay analysis.

Wilson LS, Blonquist TM, Hong F, Halpenny B, Wolpin S, Chang P, Filson CP, Master VA, Sanda MG, Chien GW, Jones RA, Krupski TL, Berry DL.

BMC Med Inform Decis Mak. 2019 Jan 9;19(1):6. doi: 10.1186/s12911-018-0725-4.

8.

Impact of prebiopsy magnetic resonance imaging of the prostate on cancer detection and treatment patterns.

Liu W, Patil D, Howard DH, Moore RH, Wang H, Sanda MG, Filson CP.

Urol Oncol. 2019 Mar;37(3):181.e15-181.e21. doi: 10.1016/j.urolonc.2018.11.004. Epub 2018 Dec 1.

PMID:
30514604
9.

Elevated Serum Cytokines and Trichomonas vaginalis Serology at Diagnosis Are Not Associated With Higher Gleason Grade or Lethal Prostate Cancer.

Vicier C, Werner L, Chipman J, Harshman LC, Patil DH, Fichorova RN, Rider JR, Sanda MG, Mucci LA, Sweeney CJ.

Clin Genitourin Cancer. 2019 Feb;17(1):32-37. doi: 10.1016/j.clgc.2018.09.022. Epub 2018 Oct 4.

PMID:
30348512
10.

Predicting erectile function following external beam radiation therapy or brachytherapy for prostate cancer using EPIC-CP.

Mihalcik SA, Chipman JJ, Sanda MG, Regan MM, Kaplan ID, Wagner AA, Crociani CM, Chang P; PROST-QA Consortium.

Pract Radiat Oncol. 2018 Nov - Dec;8(6):445-451. doi: 10.1016/j.prro.2018.04.007. Epub 2018 Apr 14. No abstract available.

PMID:
29935957
11.

Adoption of Prebiopsy Magnetic Resonance Imaging for Men Undergoing Prostate Biopsy in the United States.

Liu W, Patil D, Howard DH, Moore RH, Wang H, Sanda MG, Filson CP.

Urology. 2018 Jul;117:57-63. doi: 10.1016/j.urology.2018.04.007. Epub 2018 Apr 18.

PMID:
29679601
12.

Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator.

Ankerst DP, Goros M, Tomlins SA, Patil D, Feng Z, Wei JT, Sanda MG, Gelfond J, Thompson IM, Leach RJ, Liss MA.

Eur Urol Focus. 2019 Jan;5(1):54-61. doi: 10.1016/j.euf.2018.01.010. Epub 2018 Feb 13.

13.

Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options.

Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, Freedland SJ, Greene K, Klotz LH, Makarov DV, Nelson JB, Rodrigues G, Sandler HM, Taplin ME, Treadwell JR.

J Urol. 2018 Apr;199(4):990-997. doi: 10.1016/j.juro.2018.01.002. Epub 2018 Jan 10.

PMID:
29331546
14.

In-bore MRI-guided biopsy: can it optimize the need for periodic biopsies in prostate cancer patients undergoing active surveillance? A pilot test-retest reliability study.

Elfatairy KK, Filson CP, Sanda MG, Osunkoya AO, Geller RL, Nour SG.

Br J Radiol. 2018 Apr;91(1084):20170603. doi: 10.1259/bjr.20170603. Epub 2018 Feb 13.

15.

Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options.

Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, Freedland SJ, Greene K, Klotz LH, Makarov DV, Nelson JB, Rodrigues G, Sandler HM, Taplin ME, Treadwell JR.

J Urol. 2018 Mar;199(3):683-690. doi: 10.1016/j.juro.2017.11.095. Epub 2017 Dec 15. Review.

PMID:
29203269
16.

Patients with Intermediate Risk Prostate Cancer May be Good Candidates for Active Surveillance: Pro.

Sanda MG.

J Urol. 2017 Nov;198(5):997-999. doi: 10.1016/j.juro.2017.08.089. Epub 2017 Sep 22. Review. No abstract available.

PMID:
28947083
17.

Decision Support with the Personal Patient Profile-Prostate: A Multicenter Randomized Trial.

Berry DL, Hong F, Blonquist TM, Halpenny B, Filson CP, Master VA, Sanda MG, Chang P, Chien GW, Jones RA, Krupski TL, Wolpin S, Wilson L, Hayes JH, Trinh QD, Sokoloff M, Somayaji P.

J Urol. 2018 Jan;199(1):89-97. doi: 10.1016/j.juro.2017.07.076. Epub 2017 Jul 25.

18.

Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.

Sanda MG, Feng Z, Howard DH, Tomlins SA, Sokoll LJ, Chan DW, Regan MM, Groskopf J, Chipman J, Patil DH, Salami SS, Scherr DS, Kagan J, Srivastava S, Thompson IM Jr, Siddiqui J, Fan J, Joon AY, Bantis LE, Rubin MA, Chinnayian AM, Wei JT; and the EDRN-PCA3 Study Group, Bidair M, Kibel A, Lin DW, Lotan Y, Partin A, Taneja S.

JAMA Oncol. 2017 Aug 1;3(8):1085-1093. doi: 10.1001/jamaoncol.2017.0177.

19.

External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life.

Gay HA, Sanda MG, Liu J, Wu N, Hamstra DA, Wei JT, Dunn RL, Klein EA, Sandler HM, Saigal CS, Litwin MS, Kuban DA, Hembroff L, Regan MM, Chang P; Prostate Cancer Outcomes and Satisfaction with Treatment Quality Assessment Consortium, Michalski JM.

Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):304-317. doi: 10.1016/j.ijrobp.2017.02.019. Epub 2017 Feb 22.

20.

Detection of prostate cancer-specific transcripts in extracellular vesicles isolated from post-DRE urine.

Pellegrini KL, Patil D, Douglas KJS, Lee G, Wehrmeyer K, Torlak M, Clark J, Cooper CS, Moreno CS, Sanda MG.

Prostate. 2017 Jun;77(9):990-999. doi: 10.1002/pros.23355. Epub 2017 Apr 17.

21.

Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4.

Sowalsky AG, Kissick HT, Gerrin SJ, Schaefer RJ, Xia Z, Russo JW, Arredouani MS, Bubley GJ, Sanda MG, Li W, Ye H, Balk SP.

Clin Cancer Res. 2017 Jul 15;23(14):3823-3833. doi: 10.1158/1078-0432.CCR-16-2414. Epub 2017 Jan 24.

22.

Evaluation of a 24-gene signature for prognosis of metastatic events and prostate cancer-specific mortality.

Pellegrini KL, Sanda MG, Patil D, Long Q, Santiago-Jiménez M, Takhar M, Erho N, Yousefi K, Davicioni E, Klein EA, Jenkins RB, Karnes RJ, Moreno CS.

BJU Int. 2017 Jun;119(6):961-967. doi: 10.1111/bju.13779. Epub 2017 Feb 11.

23.

Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy: Detailed Assessment of Rectal Bleeding.

Lee JY, Daignault-Newton S, Heath G, Scarlett S, Sanda MG, Chang P, Regan MM, Michalski JM, Sandler HM, Feng FY, Kuban DA, Zietman AL, Ciezki JP, Kaplan ID, Crociani C, McLaughlin WP, Mantz CA, Finkelstein SE, Suy S, Collins SP, Garin O, Ferrer M, Hamstra DA, Spratt DE.

Int J Radiat Oncol Biol Phys. 2016 Nov 15;96(4):770-777. doi: 10.1016/j.ijrobp.2016.07.038. Epub 2016 Aug 3.

PMID:
27663760
24.

Relief of Urinary Symptom Burden after Primary Prostate Cancer Treatment.

Chang P, Regan MM, Ferrer M, Guedea F, Patil D, Wei JT, Hembroff LA, Michalski JM, Saigal CS, Litwin MS, Hamstra DA, Kaplan ID, Ciezki JP, Klein EA, Kibel AS, Sandler HM, Dunn RL, Crociani CM, Sanda MG; PROST-QA Consortium.

J Urol. 2017 Feb;197(2):376-384. doi: 10.1016/j.juro.2016.08.101. Epub 2016 Sep 2.

25.

Clinical Use of Expanded Prostate Cancer Index Composite for Clinical Practice to Assess Patient Reported Prostate Cancer Quality of Life Following Robot-Assisted Radical Prostatectomy.

Wagner AA, Cheng PJ, Carneiro A, Dovirak O, Khosla A, Taylor KN, Crociani CM, McAnally KC, Percy A, Dewey LE, Sanda MG, Chang P.

J Urol. 2017 Jan;197(1):109-114. doi: 10.1016/j.juro.2016.07.080. Epub 2016 Jul 27.

PMID:
27475967
26.

Gleason Misclassification Rate Is Independent of Number of Biopsy Cores in Systematic Biopsy.

Quintana L, Ward A, Gerrin SJ, Genega EM, Rosen S, Sanda MG, Wagner AA, Chang P, DeWolf WC, Ye H.

Urology. 2016 May;91:143-9. doi: 10.1016/j.urology.2015.12.089. Epub 2016 Mar 2.

27.

Erectile Dysfunction and Sexual Problems Two to Three Years After Prostatectomy Among American, Norwegian, and Spanish Patients.

Storås AH, Sanda MG, Boronat OG, Chang P, Patil D, Crociani C, Suarez JF, Cvancarova M, Loge JH, Fosså SD.

Clin Genitourin Cancer. 2016 Jun;14(3):e265-73. doi: 10.1016/j.clgc.2015.10.009. Epub 2015 Oct 26.

PMID:
26778476
28.

Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort.

Newcomb LF, Thompson IM Jr, Boyer HD, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Ellis WJ, Fazli L, Feng Z, Gleave ME, Kunju P, Lance RS, McKenney JK, Meng MV, Nicolas MM, Sanda MG, Simko J, So A, Tretiakova MS, Troyer DA, True LD, Vakar-Lopez F, Virgin J, Wagner AA, Wei JT, Zheng Y, Nelson PS, Lin DW; Canary PASS Investigators.

J Urol. 2016 Feb;195(2):313-20. doi: 10.1016/j.juro.2015.08.087. Epub 2015 Aug 29.

29.

The transcription factor ERG increases expression of neurotransmitter receptors on prostate cancer cells.

Kissick HT, On ST, Dunn LK, Sanda MG, Asara JM, Pellegrini KL, Noel JK, Arredouani MS.

BMC Cancer. 2015 Aug 27;15:604. doi: 10.1186/s12885-015-1612-3.

30.

Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy.

Evans JR, Zhao S, Daignault S, Sanda MG, Michalski J, Sandler HM, Kuban DA, Ciezki J, Kaplan ID, Zietman AL, Hembroff L, Feng FY, Suy S, Skolarus TA, McLaughlin PW, Wei JT, Dunn RL, Finkelstein SE, Mantz CA, Collins SP, Hamstra DA; PROSTQA Study Consortium.

Radiother Oncol. 2015 Aug;116(2):179-84. doi: 10.1016/j.radonc.2015.07.016. Epub 2015 Aug 11.

PMID:
26276528
31.

Usability evaluation and adaptation of the e-health Personal Patient Profile-Prostate decision aid for Spanish-speaking Latino men.

Berry DL, Halpenny B, Bosco JLF, Bruyere J Jr, Sanda MG.

BMC Med Inform Decis Mak. 2015 Jul 24;15:56. doi: 10.1186/s12911-015-0180-4.

32.

The role of active vaccination in cancer immunotherapy: lessons from clinical trials.

Kissick HT, Sanda MG.

Curr Opin Immunol. 2015 Aug;35:15-22. doi: 10.1016/j.coi.2015.05.004. Epub 2015 Jun 3. Review.

PMID:
26050634
33.

RNA biomarkers to facilitate the identification of aggressive prostate cancer.

Pellegrini KL, Sanda MG, Moreno CS.

Mol Aspects Med. 2015 Nov;45:37-46. doi: 10.1016/j.mam.2015.05.003. Epub 2015 May 27. Review.

34.

Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men.

de la Calle C, Patil D, Wei JT, Scherr DS, Sokoll L, Chan DW, Siddiqui J, Mosquera JM, Rubin MA, Sanda MG.

J Urol. 2015 Jul;194(1):65-72. doi: 10.1016/j.juro.2015.01.091. Epub 2015 Jan 28.

35.

Quality of life after primary treatment for localized prostate cancer: long-term considerations.

Alemozaffar M, Sanda MG.

Eur Urol. 2015 Oct;68(4):609-10. doi: 10.1016/j.eururo.2014.12.003. Epub 2014 Dec 18. No abstract available.

PMID:
25533419
36.

Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form.

Skolarus TA, Dunn RL, Sanda MG, Chang P, Greenfield TK, Litwin MS, Wei JT; PROSTQA Consortium.

Urology. 2015 Jan;85(1):101-5. doi: 10.1016/j.urology.2014.08.044.

37.

The prostate health index selectively identifies clinically significant prostate cancer.

Loeb S, Sanda MG, Broyles DL, Shin SS, Bangma CH, Wei JT, Partin AW, Klee GG, Slawin KM, Marks LS, van Schaik RH, Chan DW, Sokoll LJ, Cruz AB, Mizrahi IA, Catalona WJ.

J Urol. 2015 Apr;193(4):1163-9. doi: 10.1016/j.juro.2014.10.121. Epub 2014 Nov 15.

38.

Can urinary PCA3 supplement PSA in the early detection of prostate cancer?

Wei JT, Feng Z, Partin AW, Brown E, Thompson I, Sokoll L, Chan DW, Lotan Y, Kibel AS, Busby JE, Bidair M, Lin DW, Taneja SS, Viterbo R, Joon AY, Dahlgren J, Kagan J, Srivastava S, Sanda MG.

J Clin Oncol. 2014 Dec 20;32(36):4066-72. doi: 10.1200/JCO.2013.52.8505. Epub 2014 Nov 10.

39.

Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.

Taplin ME, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, Sanda MG, Davis JW, Loda M, True LD, Troncoso P, Ye H, Lis RT, Marck BT, Matsumoto AM, Balk SP, Mostaghel EA, Penning TM, Nelson PS, Xie W, Jiang Z, Haqq CM, Tamae D, Tran N, Peng W, Kheoh T, Molina A, Kantoff PW.

J Clin Oncol. 2014 Nov 20;32(33):3705-15. doi: 10.1200/JCO.2013.53.4578. Epub 2014 Oct 13.

40.

Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification.

Park K, Chen Z, MacDonald TY, Siddiqui J, Ye H, Erbersdobler A, Shevchuk MM, Robinson BD, Sanda MG, Chinnaiyan AM, Beltran H, Rubin MA, Mosquera JM.

Hum Pathol. 2014 Oct;45(10):2136-43. doi: 10.1016/j.humpath.2014.06.008. Epub 2014 Jun 26.

41.

Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials.

Chen RC, Chang P, Vetter RJ, Lukka H, Stokes WA, Sanda MG, Watkins-Bruner D, Reeve BB, Sandler HM.

J Natl Cancer Inst. 2014 Jul 8;106(7). pii: dju132. doi: 10.1093/jnci/dju132. Print 2014 Jul. Review.

42.

Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation.

Kissick HT, Sanda MG, Dunn LK, Pellegrini KL, On ST, Noel JK, Arredouani MS.

Proc Natl Acad Sci U S A. 2014 Jul 8;111(27):9887-92. doi: 10.1073/pnas.1402468111. Epub 2014 Jun 23.

43.

Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer.

Ankerst DP, Hoefler J, Bock S, Goodman PJ, Vickers A, Hernandez J, Sokoll LJ, Sanda MG, Wei JT, Leach RJ, Thompson IM.

Urology. 2014 Jun;83(6):1362-7. doi: 10.1016/j.urology.2014.02.035.

44.

Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response.

Kissick HT, Sanda MG, Dunn LK, Arredouani MS.

PLoS One. 2014 Apr 1;9(4):e93231. doi: 10.1371/journal.pone.0093231. eCollection 2014.

45.

Localized prostate cancer in Norway, the United States, and Spain: between-country differences of variables before treatment among patients eligible for curative treatment.

Storås AH, Sanda MG, Ferrer M, Loge JH, Dahl AA, Steinsvik EA, Guedea F, Cvancarova M, Fosså SD.

Clin Genitourin Cancer. 2014 Aug;12(4):e117-25. doi: 10.1016/j.clgc.2013.12.007. Epub 2014 Jan 3.

46.

Dose to the inferior rectum is strongly associated with patient reported bowel quality of life after radiation therapy for prostate cancer.

Stenmark MH, Conlon AS, Johnson S, Daignault S, Litzenberg D, Marsh R, Ritter T, Vance S, Kazzi N, Feng FY, Sandler H, Sanda MG, Hamstra DA.

Radiother Oncol. 2014 Feb;110(2):291-7. doi: 10.1016/j.radonc.2014.01.007. Epub 2014 Feb 4.

PMID:
24507766
47.

Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer.

Hoppe BS, Michalski JM, Mendenhall NP, Morris CG, Henderson RH, Nichols RC, Mendenhall WM, Williams CR, Regan MM, Chipman JJ, Crociani CM, Sandler HM, Sanda MG, Hamstra DA.

Cancer. 2014 Apr 1;120(7):1076-82. doi: 10.1002/cncr.28536. Epub 2013 Dec 30.

48.

Satisfaction with information used to choose prostate cancer treatment.

Gilbert SM, Sanda MG, Dunn RL, Greenfield TK, Hembroff L, Klein E, Saigal CS, Pisters L, Michalski J, Sandler HM, Litwin MS, Wei JT.

J Urol. 2014 May;191(5):1265-71. doi: 10.1016/j.juro.2013.12.008. Epub 2013 Dec 12.

49.

Survivorship after prostate cancer treatment: spouses' quality of life at 36 months.

Harden J, Sanda MG, Wei JT, Yarandi HN, Hembroff L, Hardy J, Northouse L.

Oncol Nurs Forum. 2013 Nov;40(6):567-73. doi: 10.1188/13.ONF.567-573.

50.

Development of a peptide-based vaccine targeting TMPRSS2:ERG fusion-positive prostate cancer.

Kissick HT, Sanda MG, Dunn LK, Arredouani MS.

Cancer Immunol Immunother. 2013 Dec;62(12):1831-40. doi: 10.1007/s00262-013-1482-y. Epub 2013 Oct 23.

Supplemental Content

Loading ...
Support Center